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This study aimed to determine the cellular aging of osteophyte-derived mesenchymal cells (oMSCs) in comparison to patient-matched bone
marrow stromal cells (bMSCs). Extensive expansion of the cell cultures was performed and early and late passage cells (passages 4 and 9,
respectively) were used to study signs of cellular aging, telomere length, telomerase activity, and cell-cycle-related gene expression. Our
results showed that cellular aging was more prominent in bMSCs than in oMSCs, and that oMSCs had longer telomere length in late passages
compared with bMSCs, although there was no significant difference in telomere lengths in the early passages in either cell type. Telomerase
activity was detectable only in early passage oMSCs and not in bMSCs. In osteophyte tissues telomerase-positive cells were found to be located
perivascularly and were Stro-1 positive. Fifteen cell-cycle regulator genes were investigated and only three genes (APC, CCND2, and BMP2)
were differentially expressed between bMSC and oMSC. Our results indicate that oMSCs retain a level of telomerase activity in vitro, which
may account for the relatively greater longevity of these cells, compared with bMSCs, by preventing replicative senescence. J. Cell. Biochem.
108: 839–850, 2009.  2009 Wiley-Liss, Inc.KEY WORDS: OSTEOPHYTE; MESENCHYMAL STEM CELL; TELOMERE LENGTH; TELOMERASE ACTIVITY; LONGEVITY; SENESCENCE; OSTEOARTHRITISM esenchymal stem cells (MSCs) have a central role inregenerative medicine because of their multipotent
nature and ability for self-renewal. Morphological and proteomic
characteristics of MSCs, in particularly bone marrow stromal cells
(bMSCs), have been extensively studied and are used for their
identification. In our previously published study, MSCs were
isolated and characterized from osteophyte tissues and it was
shown that osteophyte-derived mesenchymal cells (oMSCs) were
comparable to bMSCs with respect to morphology, cell surface
antigen expression, differentiation potentials, and immunological
response. The oMSCs were also found to have a much greater
capacity for population doublings than bMSCs [Singh et al., 2008].
MSCs from various tissues have been isolated and compared to
bMSCs, but there are no studies, to our knowledge, comparing site-
specific differences between cells from the same patients. In fact, one
of the major hurdles facing the successful therapeutic application of
bMSCs is the limited number of MSCs that can be generated from
bone marrow due to their limited lifespan in vitro. It is known that
bMSCs only have in vivo telomerase activity and readily succumb to
replicative senescence, limiting their in vitro proliferation potential
[Banfi et al., 2002]. As far as we know, there are no published studiesrant sponsor: Queensland Orthopaedic Trust.
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The longevity of a cell population depends on the phenomenon of
replicative senescence, first described by Hayflick [1985]. Replica-
tive senescence is marked by the progressive shortening of the
telomeres and various other mechanisms such as changes in gene
expression during long-term culture condition resulting in DNA
damage. These factors play a role in promoting cellular aging,
characterized by MSCs becoming enlarged and irregular in shape
and ultimately a complete cessation of proliferation. Telomerase
reverse transcriptase (hTERT) is a highly specialized ribonucleo-
protein complex, which maintains telomere length by adding
telomeric TTAGGG repeats to the 30 ends of human chromosomes
[Broccoli et al., 1995]. This process protects the 30 end of the single-
strand DNA overhang which has been shown to be most important
for cellular integrity [Blackburn, 2001; Baird, 2008]. In the event
that telomerase activity is inhibited or suppressed, telomeres become
shortened and cells rapidly succumb to senescence and apoptosis.
Telomerase activity has been found to be widely distributed among
renewing human tissues and concentrated in the areas of stem cells839
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and actively multiplying transit cells [Rubin, 2002]. Evidence of
telomerase activity in normal somatic tissues have been found in
bone marrow and peripheral blood leukocytes [Broccoli et al., 1995;
Counter et al., 1995; Hiyama et al., 1995], epidermis [Harle-Bachor
and Boukamp, 1996] as well as in cells that have ‘‘replenishing’’
roles such as cells in the skin and gut mucosa. Dysregulation of
telomerase activity results in uncontrolled malignant tumor growth
[Dhaene et al., 2000]. Several studies have shown that cancer cells
also have increased telomerase activity which stops telomere
shortening and enhances their self-renewal ability and resistance to
apoptosis, effectively rendering them immortal [Fujiwara, 2009;
Proctor et al., 2009; Schmelzer and Reid, 2009; Shaker et al., 2009].
The loss of telomerase activity has been associated with disease
and it has been demonstrated in vitro in diseased osteoblasts and
chondrocytes. This may be of significance to the progression of
osteoarthritis (OA) and may also be correlated with osteopenia
[Yudoh and Nishioka, 2004]. However, telomerase activity in
osteophyte tissues and cells is still not known.
The aim of this study was to compare the longevity of patient-
matched bMSCs and oMSCs and to determine what relationship
exists between telomerase activity, telomere length, and cell
senescence with respect to a cell type’s in vitro longevity.
MATERIALS AND METHODS
TISSUE SAMPLES
Osteophyte tissues were collected from five patients after informed
consent was given. The patients were between 65 and 78 years of age
undergoing elective knee replacement surgery. Bone marrow was
also collected from the same patients by bone marrow aspirate
[Singh et al., 2008]. All procedures were done in accordance with the
ethics guidelines of the Queensland University of Technology and
Prince Charles Hospital, Brisbane, Australia.
MSC CULTURE AND CHARACTERIZATION
The osteophyte tissues were placed in sterile containers with 10 ml of
Hanks buffer (Gibco, Invitrogen, Mount Waverley, VIC, Australia).
Superficial fibrous cartilage was discarded, and 2 mm segments were
dissected along the tissue and placed in six-well plates with 2 ml of
low glucose DMEM (Gibco) with 10% (v/v) fetal bovine serum (FBS)
(HyClone, Logan, UT) and 1% (v/v) penicillin and streptomycin
(Gibco). Confluent cultures were trypsinized and passaged before
cryopreservation. bMSCs and oMSCs were isolated and charac-
terized according to a previously published method [Mareddy
et al., 2007; Singh et al., 2008]. Briefly, bMSCs were isolated
by Lymphoprep (Axis-Sheild PoC AS, Oslo, Norway) gradient
sedimentation and oMSCs were isolated from explant cultures.
Cells isolated from osteophyte tissue and bone marrow aspirates
at passage 4 were trypsinized and incubated for 30 min on ice with
antibodies for the following cell surface antigens: CD45 (leukocyte
marker), CD34 (hematopoietic stem cells), CD44, CD29, CD166
(adhesion related), CD90, CD105, CD73 (mesenchymal/stromal stem
cells), MHC I, and MHC II. All antibodies were from Becton
Dickinson Biosciences (NJ). Single-color staining was performed
using a phycoerythrin (PE)-conjugated secondary antibody (Becton
Dickinson Biosciences, NJ) and analyzed using a fluorescence-840 CELL SENESCENCE OF OSTEOPHYTE-DERIVED CELLSactivated cell sorter (FACS Vantage SE; Becton Dickinson, UK) using
a 575-nm band pass filter for red PE fluorescence. Data were
analyzed using WinMDI 2.8 software.
Cells at passages 3–5 were differentiated into chondrocytes
according to micro-mass pellet culture. Briefly, cells (2.5 105) were
placed in serum-free medium consisting of high glucose DMEM
supplemented with 10 ng/ml TGF-b3, 100 nM dexamethasone,
50mg/ml ascorbic acid 2-phosphate, 100mg/ml sodium pyruvate,
40mg/ml proline, and a commercial preparation of ITS-plus
(final concentration: 6.25mg/ml insulin, 6.25mg/ml transferrin,
6.25mg/ml selenous acid, 5.33mg/ml linoleic acid, and 1.25 mg/ml
bovine serum albumin) (Sigma–Aldrich, NSW, Australia). Cell
pellets were formed by centrifugation at 500g for 15 min, and then
cell pellets were cultured in the chondrogenetic induction medium
mentioned above for a further 3 weeks. The pellets were fixed with
4% paraformaldehyde and matrix deposition of proteoglycans
was detected by Alcian blue stain. Osteogenic differentiation of
subconfluent osteophyte monolayers (passages 3–5) was induced by
medium containing 50mM ascorbic acid 2-phosphate, 10 mM
b-glycerol phosphate, and 100 nM dexamethasone in DMEM with
10% FBS. This medium was changed twice weekly for up to 3 weeks.
Following 4% paraformaldehyde fixation, cell and matrix miner-
alization was detected by Alizarin red stain for calcium deposits.
Confluent cultures of oMSCs and bMSCs at 3–5 passages undergoing
adipogenic differentiation were induced using medium containing
0.5 mM isobutylmethyl xanthine, 100–200mM indomethacin, 1mM
dexamethasone, and 10mg/ml insulin in DMEM with 10% FBS. The
cells were treated in this medium for 3 days, and then the medium
was changed to adipogenic maintenance medium (DMEM with 10%
FBS and 10mg/ml insulin) alone for 24 h. After three cycles, cells
were cultured in maintenance media for another 21 days. Cells were
fixed with 4% paraformaldehyde and stained with oil red O to detect
the lipid droplets in the differentiated cells.
CELL SENESCENCE ASSAY
Cytochemical staining for senescence associated b-galactosidase
assay was performed using a b-galactosidase staining kit (Cell
Signaling Technology, Beverly, MA). Cells from passage 4 (P4) and
passage 9 (P9) were seeded at a density of 2 104/well into four-well
plates and allowed to attach overnight, then washed with PBS, fixed,
and incubated overnight at 378C with X-gal chromogenic substrate
at pH 6.0 according to manufacturer’s protocol. The color
development was observed under light microscope and the image
was captured at 100magnification. The percentage of stained cells
was calculated from the averages from five MSC cultures from both
early and late passages.
CELL PROLIFERATION (3H LEUCINE INCORPORATION)
To compare the capacity of cell proliferation between oMSCs and
bMSCs, cell proliferation was conducted at the 4th and 9th passage
using 3H leucine incorporation assay [Singh et al., 2008]. Briefly,
BMSCs and oMSCs at the 4th and 9th passage were seeded in 24-well
plates at 1 104 cells per well. 3H-leucine was added at (1mCi/ml) to
each well. Proliferation was assessed on day 2. Cell number was
quantified by the amount of 3H leucine-labeled protein. Briefly, cells
were washed with Hank buffer salt solution twice, then incubatedJOURNAL OF CELLULAR BIOCHEMISTRY
with 2 ml of 10% trichloroacetic acid. This was followed by two
washes with distilled water and then incubated with 1 ml of caustic
triton overnight. To produce a homogenous protein solution, plates
were placed on a plate shaker for 1 h, then 100ml samples were
aliquoted into 96-well isotope plate. Radioactivity was measured
by a scintillation counter (Wallac Microbeta Trilux, USA). All
experiments were performed in triplicate.
TELOMERE LENGTH ASSAY
This protocol was adapted from Cawthorn et al. [Cawthon, 2002].
Telomere (T) PCR and single copy gene (S) PCR were performed in
separate plates. Two master mixes of PCR reagents—one with the
T primer pair and one with the S primer pair—were prepared. Thirty
microliters of T master mix was added to each sample well and
standard curve well of the first plate, and 30ml of S master mix was
added to each sample well and standard curve well of the second
plate. For each individual whose T/S ratio was assayed, three
identical 20ml aliquots of the DNA sample (35 ng/aliquot) were
added to Plate 1 and another three aliquots were added to the same
well positions in Plate 2. For each standard curve, one reference DNA
sample was serial diluted in TE-4 by 1.68-fold per dilution to
produce five concentrations of DNA ranging from 0.63 to 5 ng/ml,
and which were then distributed in 20ml aliquots to the standard
curve wells of each plate.
The final concentrations of reagents in the PCR were 150nM 6-ROX
and 0.2 Sybr Green I (Molecular Probes), 15 mM Tris–HCl, pH 8.0,
50 mM KCl, 2 mM MgCl2, 0.2 mM each dNTP, 5 mM DTT, 1% DMSO,
and 1.25 U AmpliTaq Gold DNA polymerase (Applied Biosystems,
Scoresby, VIC, Australia). The final telomere primer concentrations
were: T1, 270 nM; T2, 900 nM. The final 36B4 (single copy gene)
primer concentrations were: 36B4u, 300 nM; 36B4d, 500 nM. The
primer sequences were:
T1: 50-GGTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT-30.
T2: 50-TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA-30.
36B4u: 50-CAGCAAGTGGGAAGGTGTAATCC-30.
36B4d: 50-CCCATTCTATCATCAACGGGTACAA-30.
All polymerase chain reactions were performed using the ABI Prism
7700 Sequence Detection System (Applied Biosystems). The thermal
cycling profiles were as follows: 10min activation step at 958C; then
for the telomere Plate 18 cycles of 958C for 15 s, 548C for 2min and for
the 36B4 Plate 30 cycles of 958C for 15 s, 588C for 1min. The data were
analyzed using the SDS 1.7 software to generate a standard curve for
each plate and to determine the dilution factors of standards
corresponding to the T and S amounts in each sample.
TELOMERASE ACTIVITY ASSAY
Telomerase activity in P4 and P9 oMSC and bMSC was assayed using
a TRAPeze Detection Kit (Chemicon International, CA). Briefly, cells
were lysed and endogenous telomerase activity evaluated in the
supernatant based on its extension of a telomerase template.
Products were visualized on 2% acrylamide gels stained in
SYBRGreen (Invitrogen) and analyzed by Fluorimager SI (Molecular
Dynamics, CA). The presence of telomerase activity was indicated by
a ladder of 6-mer products as shown by the positive control.JOURNAL OF CELLULAR BIOCHEMISTRYFLOW CYTOMETRIC ANALYSIS
Passage 4 and 9 oMSCs and bMSCs were analyzed for the presence of
telomerase by flow cytometry. Cells (3 104) were used for the
assay by fixation into a well of 96-well plate containing 100ml of
4% paraformaldehyde solution for 15 min, washed twice with
washing buffer (PBS with 0.01% BSA) by centrifuging the cells at
a speed of 1,350 rpm for 3 min each, then permeabilized with
95% ice-cold methanol for 30 min, followed by a further two
washes. The cells were incubated with the hTERT rabbit polyclonal
antibody EST21A (Alpha Diagnostic International, TX; 1:50
dilution) at 48C overnight. On day 2 the cells were washed twice
with washing buffer and incubated with a PE-conjugated secondary
antibody (Becton Dickinson Biosciences, NJ) for 30 min at room
temperature.
For Stro-1 expression, cells were incubated with a Stro-1
antibody (Becton Dickinson Biosciences, NJ) for 30 min, washed
twice with PBS, and incubated with Alexa Fluor 488-conjugated
secondary antibody (Becton Dickinson Biosciences, NJ) for 20 min,
then washed and diluted in 50ml of staining buffer before analysis.
The fluorescence intensity of positively stained samples was
compared to unstained, as well as isotope-matched negative
controls. Mononuclear cells were gated according to a combination
of forward scatter (FCS), side scatter (SSC), and absence of PE
fluorescence.
QUANTITATIVE REAL-TIME PCR
oMSCs and bMSCs at P4 were analyzed for the mRNA expression of
15 cell-cycle-related genes (Table I). Total RNA was extracted
with Trizol (Invitrogen) according to the manufacturer’s instruc-
tions. Both primers and reagents were supplied as part of the
Superarray RT2 Profiler plates (Superarray Bioscience Corporation,
Jomar Biosciences, Kensington, SA, Australia) for human stem-cell-
related genes. PCR cycle conditions were as follows: 958C for 5 min
followed by 40 cycles at 958C for 30 s and 588C for 30 s. Cycle
threshold (Ct) values were used to perform calculations. The
relative expressions of genes were calculated on the data analysis
template provided in the kit (Ct values were normalized against five
housekeeping genes). The expression of mRNA of each gene relative
to housekeeping mRNA is expressed as 2DCt . The P-value and fold
changes were calculated by the functions in the template.
KARYOTYPING
Passage 4 and 9 oMSCs and bMSCs were sent to Sullivan and
Nicolaides Pathology Services (Brisbane, QLD, Australia) for
karyotyping study. The cells were processed and metaphases of
cells were Q-banded and chromosomes karyotyped according to the
recommendations set out in the International System for Human
Cytogenetic Nomenclature.
IMMUNOHISTOCHEMISTRY
Osteophyte tissues from five patients were demineralized, processed,
and embedded in paraffin wax. The tissues were cut in 5mm serial
sections for immunohistochemical staining. Briefly, sections were
incubated with a 1:100 dilution of the hTERT antibody EST21A or
1:100 dilution of Stro-1 antibody overnight at 48C. The sections
were incubated with a biotinylated swine-antimouse, rabbit, goatCELL SENESCENCE OF OSTEOPHYTE-DERIVED CELLS 841
TABLE I. Cell-Cycle Regulator Gene Expression in oMSCs and bMSCs
RefSeq Symbol Description Gene name oMSC/bMSC P-value
NM_001237 CCNA2 Cyclin A2 CCN1/CCNA 1.96 0.3054
NM_053056 CCND1 Cyclin D1 BCL1/D11S287E 1.15 0.6379
NM_001759 CCND2 Cyclin D2 KIAK0002 2.93 0.0459
NM_001238 CCNE1 Cyclin E1 CCNE 1.48 0.1380
NM_001786 CDC2 Cell division cycle 2, G1 to S and G2 to M CDC28A/CDK1 1.68 0.3849
NM_001791 CDC42 Cell division cycle 42 (GTP binding protein, 25 kDa) CDC42Hs/G25K 1.24 0.6716
NM_016204 GDF2 Growth differentiation factor 2 BMP-9/BMP9 1.32 0.2594
NM_020634 GDF3 Growth differentiation factor 3 GDF3 4.49 0.8135
NM_001527 HDAC2 Histone deacetylase 2 RPD3/YAF1 1.42 0.8208
NM_032188 MYST1 MYST histone acetyltransferase 1 MOF/hMOF 1.39 0.7213
NM_007067 MYST2 MYST histone acetyltransferase 2 HBO1/HBOA 1.02 0.8178
NM_016948 PARD6A Par-6 partitioning defective 6 PAR-6A/PAR6 1.03 0.8167
NM_000321 RB1 Retinoblastoma 1 (including osteosarcoma) OSRC/RB 1.90 0.7854
NM_001200 BMP2 Bone morphogenic protein 2 BMP2A 3.37 0.0195
NM_000038 APC Adenomatous polyposis coli DP2/DP3 1.47 0.0347antibody (Dako Multilink, CA) for 15 min, followed by 15 min
incubation with horseradish peroxidase-conjugated avidin–biotin
complex. Antibody complexes were visualized by the addition of a
buffered diaminobenzidine (DAB) substrate for 4 min and lightly
counterstained with Mayer’s hematoxylin.
RESULTS
MESENCHYMAL STEM CELLS IN OSTEOPHYTE TISSUE AND
OSTEOPHYTE-DERIVED CELLS (oMSCS)
Cells in osteophyte tissue showed expression for the primitive
mesenchymal marker Stro-1, especially in areas with new tissue
formation (Fig. 1C,D). Immunohistochemical analysis found a
large number of cells around the newly formed bone tissue staining
positive for Stro-1 (Fig. 1D). The presence of telomerase-positive
cells was also identified in the osteophyte tissue (Fig. 1E,F). Most
telomerase-positive cells were spatially located in perivascular sites
(Fig. 1E) and new bone-forming areas adjacent to the newly formed
osteoids (Fig. 1F). No Stro-1 and telomerase-positive cells were
found in mature tissue in osteophyte indicating that telomerase-
positive cells involved in renewing human tissues and concentrated
in the areas of stem cells and actively multiplying transit cells.
Stro-1 expression in oMSCs and bMSCs was also studied by flow
cytometry analysis (Fig. 2) and showed that the percentage of Stro-
1-positive cells was greater in oMSCs than in bMSCs both in early
(P4) and late (P9) passage cultures. This indicated that oMSCs
retained the surface antigen expression of Stro-1 even after
extensive population doublings, whereas bMSCs at P9 showed a
significant decrease of Stro-1-positive cells compared to oMSC
(P< 0.02).
CHARACTERIZATION OF OSTEOPHYTE-DERIVED MSCs (oMSCs)
MSCs were successfully cultured from osteophyte tissues collected
from patients undergoing knee replacement surgery. These cells
appeared as typical MSCs, adhering to culture plastic and having a
fibroblastic morphology within 24 h (Fig. 3A,i). These cells were able
to differentiate into the mesenchymal lineages producing osteogenic
(Fig. 3A,ii), chondrogenic (Fig. 3A,iii), and adipogenic (Fig. 3A,iv)
cultures. oMSC cultures were expanded greater then 10 passages and842 CELL SENESCENCE OF OSTEOPHYTE-DERIVED CELLSwere able to be re-cultured from frozen stocks that had been stored
in liquid nitrogen (results not shown).
The surface antigen phenotype of oMSCs was similar to that of a
normal MSCs (Fig. 3B). They did not express major histocompat-
ability complex class II (MHC II), but did express the class I (MHC I)
isoform. There was no contamination of oMSC cultures with
leukocytes (CD45) and hematopoietic stem cells (CD34). As there is
no specific surface antigen marker for MSCs, a panel of MSC
‘‘indicative markers’’ were used, including antigens involved in cell
adhesion (CD166, CD44, CD29) and putative stem cell markers
(CD90, CD105, CD73). oMSCs and bMSCs expressed a similar MSC-
like profile of these markers (results of bMSCs not shown).
b-GALACTOSIDASE EXPRESSION IN oMSCs AND bMSCs
b-Galactosidase staining in both oMSCs and bMSCs cultures
increased with the number of passages (Fig. 4A). Interestingly,
bMSCs showed significantly higher cell numbers with the
expression of b-galactosidase compared to oMSCs in P9. The
number of b-galactosidase-positive cells in early passage was low at
0–4% in oMSCs and 8–11% in bMSCs at P4 culture; however, at P9,
b-galactosidase-positive cells increased to 20–24% in oMSCs and
86–92% in bMSCs (Fig. 4B). The percentage of b-galactosidase-
positive cells in bMSCs was significantly higher than that in oMSCs
(P< 0.002, n¼ 5). In bMSCs increase of b-galactosidase-positive
cells in the late passage was correlated with the decrease of cell
proliferation. There was a significant decrease in cell proliferation in
P9 bMSCs compared with P4 bMSCs and P9 oMSCs. In oMSCs there
was a trend of decrease in cell proliferation during passages;
however, no statistically significant difference in cell proliferation
was found between P9 and P4 oMSCs (Fig. 4C).
TELOMERE LENGTH AND TELOMERASE ACTIVITY IN
oMSC AND bMSC
There was a significant decline of telomere length detected in
matched P9 oMSCs and bMSCs compared to the corresponding P4
cells (Fig. 5). No significant difference was seen between oMSCs
and bMSCs at P4; however, at P9 oMSC telomere length was
significantly higher than bMSC telomere length (P< 0.01).
Compared with the positive control, telomerase activity was
significantly decreased in both P4 and P9 oMSCs and bMSCs. In P4JOURNAL OF CELLULAR BIOCHEMISTRY
Fig. 1. Stro-1 and telomerase expression in osteophyte tissues. A vessel concentrated area (A) and a new bone formation area (B) were selected from osteophyte tissues. Cells
in osteophyte tissue showed expression for the primitive mesenchymal marker Stro-1 in cells related to vessels (C) and new tissue formation (D). The presence of telomerase-
positive cells was also identified in the osteophyte tissue (E,F). Most telomerase-positive cells were spatially located in perivascular sites (E) and new bone-forming areas
adjacent to the newly formed osteoids (F). A targeted area selected in C–F was enlarged and showed in the upright corner to give a better view of the positive staining. (Image
magnification: 200; B¼ bone; arrow¼ blood vessel.) [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]oMSCs low-level telomerase activity was detectable, showing a non-
continuing low molecular banding compared to controls, whereas
no activity was detectable in either P4 or P9 bMSCs or in P9 oMSCs
(Fig. 6A). Flow cytometry analysis of hTERT also revealed that the
percentage of telomerase-positive cells was significantly greater in
P4 oMSCs compared to P4 and P9 bMSCs and P9 oMSCs (P< 0.01;
Fig. 6B,C). However, in both bMSCs and oMSCs there was a
precipitous loss of telomerase activity after extensive population
doublings.
CYTOGENETIC KARYOTYPE ANALYSIS OF oMSCs AND bMSCs
Karyotypic analysis of P4 and P9 bMSCs (Fig. 7A) and oMSCs
(Fig. 7B) did not reveal any aneuploidy, abnormal metaphases, and
extensive translocation of the chromosomes or changes in the copy
number as is observed in some cancer or tumor cells. Furthermore,
when compared to bone marrow cells the cytogenetic analysis
revealed a normal chromosomal number and Q-banding patternJOURNAL OF CELLULAR BIOCHEMISTRYindicating that chromosome mitosis was typical for both cell types
(Fig. 7).
CELL-CYCLE REGULATOR GENE EXPRESSION IN
oMSCs AND bMSCs
Fifteen genes involved in cell-cycle regulation, modulation of
chromatin, and telomerase were analyzed in P4 oMSCs and bMSCs
by real-time PCR. The results showed that 12 out of the 15 cell-cycle
regulatory genes were expressed equally in both oMSCs and bMSCs
(P> 0.05, Table I), but that there was a significantly differential
expression of three genes in matched oMSCs and bMSCs
samples (P< 0.05, Table I). Cyclin D2 (CCND2) and adenomatous
polyposis coli (APC), both directly related to cell-cycle regulation,
were down-regulated in oMSC compared to bMSCs; interestingly,
bone morphogenetic protein 2 (BMP2) was more than threefold
up-regulated in oMSC.CELL SENESCENCE OF OSTEOPHYTE-DERIVED CELLS 843
Fig. 2. Flow cytometry study (FACS) of Stro-1 expression in oMSCs and bMSCs. The percentage of Stro-1-positive cells was greater in oMSCs than in bMSCs both in early (P4)
and late (P9) passage cultures (A). (B) A representative histogram plot of the Stro-1 FACS results from oMSCs and bMSCs (blue peak: negative control; red peak: positive
expression). [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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Fig. 3. Characterization of oMSCs. (A,i) Passage 4 oMSCs exhibiting a typical attached MSC fibroblastic morphology. (ii) Osteogenic differentiation—calcium deposition
stained by Alzarin red. (iii) Chondrogenic differentiation—proteoglycan deposition stained by Alician blue in pellet culture. (iv) Adipogenic differentiation— lipid droplets
stained with Oil Red O (all image magnification¼ 100). (B) Immunophenotypic characterization of oMSCs showed that oMSCs expressed a typical MSC surface antigen profile,
lacking MHC II expression, absence of contamination with leukocytes (CD45) and hematopoietic stem cells (CD34), and expressing various adhesion (CD166, CD44, CD29) and
stem cell-like (CD90, CD105, CD73) molecules. Graphs are representatives of five oMSC cultures. [Color figure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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Fig. 4. b-Galactosidase expression in oMSCs and bMSCs. b-Galactosidase
staining in P4 (i) and P9 (iii) bMSCs and P4 (ii) and P9 (iv) oMSCs showed an
increase of positive cells with the number of passages (A). bMSCs (iii) showed
significantly higher cell numbers with the expression of b-galactosidase
compared to oMSCs (iv) in P9. The number of b-galactosidase positive cells
in early passage was low showing 0–4% in oMSCs and 8–11% in bMSCs at P4
culture (B). At P9, positive cells increased to 20–24% in oMSCs and 86–92%
in bMSCs (B). The percentage of cells positively to b-galactosidase staining in
bMSCs was significantly higher than in oMSCs (P< 0.002, n¼ 5). Significantly
decreased cell proliferation was noted in P9 bMSCs when compared with P4
bMSCs and P9 oMSCs (C). In oMSCs, there was a trend of decrease in cell
proliferation during passages; however, no statistically significant difference in
cell proliferation was found between P9 and P4 oMSCs (C). [Color figure can be
viewed in the online issue, which is available at www.interscience.wiley.com.]
Fig. 5. Telomere length in oMSCs and bMSCs. There was a significant decline
of telomere length detected in matched P9 oMSCs and bMSCs compared to the
corresponding P4 cells. No significant difference was seen between oMSCs and
bMSCs at P4; however, at P9 oMSC telomere length was significantly higher
than bMSC telomere length (P< 0.01).
846 CELL SENESCENCE OF OSTEOPHYTE-DERIVED CELLSDISCUSSION
OA is a frequent cause of chronic disability and is highly prevalent in
persons over the age of 65. The etiology of OA is poorly understood
and current treatments merely alleviate the symptoms. As yet
there is no way of reversing or significantly delaying the disease
progression. Osteophytes form at the margins of articular cartilage
in the osteoarthritic joint and their formation is associated with
mesenchymal precursors from the chondro-synovial junction,
probably in response to altered biomechanics and remodeling of
the underlying bone [van der Kraan and van den Berg, 2007]. We
recently characterized osteophyte-derived cells as MSCs and found
that these cells were capable of retaining proliferative capacities at
higher passage numbers compared with patient-matched bMSCs. It
is not clear that the relationship between tissue-derived MSCs and
bMSCs even though bone marrow has been considered to be the
major reservoir of MSCs. Microenvironment where MSCs residence
plays an imperative role in determining stem cell fate. In the current
study, we found that the proliferative potential of MSCs from bone
marrow and osteophytes appeared to be closely linked to telomere
length, which is controlled by telomerase activity, and Stro-1
expression. However, there was no statistically significance in oMSC
proliferation between P9 and P4, even though telomere length and
telomerase activity were significantly decreased in P9 oMSCs. The
significantly higher telomerase activity in the early passage oMSCs
(P4) and the retaining of primitive marker Stro-1 in the late
passage oMSCs (P9) may be responsible for the maintenance of
proliferation in P9 oMSCs. Previous studies have showed that stem
cells in their niches have longer telomeres in comparison to their
more differentiated counterparts [Flores et al., 2008], but none of
the studies have compared site-specific differences in MSCs from the
same patient. This study sought to address this knowledge gap by
characterizing the presence of the telomerase subunit as well as
telomerase activity and cellular senescence in oMSCs compared toJOURNAL OF CELLULAR BIOCHEMISTRY
Fig. 6. Telomerase activity in bMSC and oMSCs. Compared with the positive control, telomerase activity was significantly decreased in both P4 and P9 oMSCs and bMSCs (A).
In P4 oMSC low-level telomerase activity was detectable, showing a non-continuing low molecular banding compared to controls, but no activity was detectable in either P4 or
P9 bMSCs or in P9 oMSCs (A). Flow cytometry analysis of hTERT also revealed that the percentage of telomerase-positive cells was significantly greater in P4 cultures of oMSCs
compared to P4 bMSCs and P9 cultures of bMSCs and oMSCs (P< 0.01; B). (C) A representative histogram plot of the hTERT FACS results from oMSCs and bMSCs (blue peak:
negative control; red peak: positive expression). [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]patient-matched bMSCs. Our data indicate that oMSC is not an
immortalized cell, since they can enter cell senescence, has
decreasing telomere length and normal karyotype, all in keeping
with the current knowledge of MSC cultures. We also found that
oMSCs may have some telomerase activity in the culture of early
passages and are able to retain a primitive undifferentiated state.
Cell differentiation plays a crucial role in declining proliferative
capacity. Stro-1 has been identified as a marker of primitive stem
cells and does not present in committed progenitors [Simmons
and Torok-Storb, 1991]. Our results show that >95% of oMSCs
retained their primitive Stro-1-positive stem cell phenotype,
whereas a significant decrease was seen in bMSCs. Previous studies
have demonstrated that MSCs can be isolated from various
regenerative tissues and that such MSCs have different functional
properties including different long-term growth kinetics [Banfi
et al., 2000; Kern et al., 2006]. Osteophyte tissues showed the
presence of highly proliferating areas, having MSCs expressing theJOURNAL OF CELLULAR BIOCHEMISTRYStro-1 marker. These results suggest that the presence of Stro-1-
positive oMSCs may be carried over from the tissues and that human
bone marrow cell populations contain partially differentiated
progenitor cells, which may be the reason that there are relatively
less Stro-1-positive bMSCs compared with oMSCs [Zimmermann
et al., 2003].
Prior studies show that the enzyme, lysosomal, b-galactosidase
(SA-b-gal) is active in senescent human fibroblasts, but not in
quiescent, pre-senescent or pre-differentiated cells. There is an
age-dependent increase in b-galactosidase expression as normal
somatic cells invariably enter a state of irreversibly arrested growth
and altered function after a finite number of cell divisions [Dimri
et al., 1995]. oMSCs showed the same characteristics as bMSCs in
that cells from both sources were prone to cellular aging in long-
term culture; however, the percentage of senescent oMSC in early
and late passages were less than bMSCs at the same population
doublings. It has also been reported that the rate of senescence isCELL SENESCENCE OF OSTEOPHYTE-DERIVED CELLS 847
Fig. 7. Cytogenetic karyotype analysis of oMSCs and bMSCs. Representative pictures of karyotype analysis of P9 bMSCs (A) and P9 oMSCs (B) did not reveal any aneuploidy,
abnormal metaphases, and extensive translocation of the chromosomes.affected by the culture conditions and repeated passage at various
densities [Colter et al., 2000; Fehrer et al., 2007]. In this study the
culture conditions and seeding densities were therefore kept as
similar as possible in both cell cultures.
The concept of ‘‘age-dependent’’ expression in cell cultures was
very distinct, not only between passages, but also between cell
sources [Fehrer et al., 2007]. When compared to our previously
reported results for cell proliferation [Singh et al., 2008], oMSCs
appeared to have either more primitive cells or be somehow more
resistant to aging. Various studies have indicated that cellular aging
may be, in part, due to critical size telomere length that leads to
replicative senescence [Yang, 2008; Britt-Compton et al., 2009;
Hanna et al., 2009; Wu et al., 2009]. Evidence suggests that stem
cells maintain longer telomeres relative to other cells within the
tissue, such as in lingual mucosa, where in situ hybridization has
revealed longer telomeres in the basal cells [Aida et al., 2008] and
stem cell compartments of the skin, small intestine, cornea, testis,
and brain [Flores et al., 2008]. One study revealed that the mean
terminal restriction fragment (TRF) may vary by as much as 5% in
individuals [Parsch et al., 2004]. In the present study a simpler
quantitative PCR-based assay was used to determine average
telomere length. Our results indicate that at both early and late
passages average telomere lengths were longer in oMSCs than
bMSCs, which implies that oMSCs are capable of undergoing more
population doublings than bMSC before reaching the critical point
of growth arrest.
Given the immune privilege and replicative potential of MSC, the
question has been raised whether MCSs may be more prone to
undergo malignant transformation. Even though MSCs derived from
healthy tissues do not appear to exhibit tumorigenic characteristics
[Bernardo et al., 2007; Serakinci et al., 2008], it remains unclear
whether MSCs derived from diseased tissues, such as osteophytes,
show adverse cytogenetic variation in comparison to MSCs from
bone marrow. It has been demonstrated clinically that most
malignant cells will exhibit some type of chromosomal rearrange-848 CELL SENESCENCE OF OSTEOPHYTE-DERIVED CELLSment or abnormalities [Popescu and Zimonjic, 2002; Zhang et al.,
2007]. The potential for stem cells to become tumorigenic as the
results of gene mutation is quite high since they are highly expanded
in vitro [Kunkel and Bebenek, 2000; Han et al., 2005]. In this study
the cytogenetic stability of oMSC and bMSCs was determined
by comparing their karyotype at early and late passages. Our
results showed that both oMSC and bMSCs were comparable
showing a normal diploid karyotype and had an absence of
aneuploidy or polyploidy. Normal chromosome structure was
verified by G-banding analysis and abnormalities such as deletion,
inversion, translocation, and rig chromosomes were not detected.
These results suggest that there is only a limited possibility of oMSCs
becoming tumorigenic as a result of extensive in vitro expansion.
Changes in proliferative gene expressions involve DNA replica-
tion, cell-cycle regulators, and chromatin modulators, all of which
have been associated with replicative senescence [Wagner et al.,
2008]. The Wnt, bone morphogenetic protein, and Notch pathways
have been found to be implicated in key roles in self-renewal and
differentiation of hematopoietic, intestinal, epidermal stem cells,
and MSCs [Satija et al., 2007]. In this study we explored differences
in expression of proliferative genes in MSCs sourced from patient-
matched bone marrow and osteophytes tissues in relation to cell
longevity. A total of 15 cell-cycle-related genes were investigated in
oMSCs and bMSCs. It was found that 12 cell-cycle-related genes
were similarly expressed between oMSCs and bMSCs, whereas the
three genes CCND2, APC, and BMP2 were differentially expressed,
with a P-value <0.05. CCND2 encodes proteins that amplify the G1
to S phase, thereby driving the cell cycle, although one study has
shown that knockdown of CCND2 only has a minor effect on cell
division [Hishida et al., 2008]. Our study found that CCND2 was
approximately threefold down-regulated in oMSCs compared with
bMSCs. This down-regulation of CCND2 did not appear to affect the
cell proliferation characteristics. APC plays a central role in Wnt
signaling pathways which modulate stem cell survival [Kim et al.,
2004] by negatively modulating the activity of cyclins [Bienz andJOURNAL OF CELLULAR BIOCHEMISTRY
Hamada, 2004]. Down-regulation of APC expression in oMSCs may
support their role in oMSC cell cycle. BMP2 plays many regulatory
roles in the maintenance of multipotency and ‘‘stemness’’ as well as
differentiation of stem cells [Lecanda et al., 1997; Fromigue et al.,
1998; Osyczka and Leboy, 2005], which may explain the observed
unregulated BMP2 expression in oMSCs.
In summary, osteophyte tissues contain pools of MSCs which
exhibit normal traits, enter senescence after extended in vitro
culture and have a normal karyotype compared to bMSCs. The
greater longevity of oMSCs relative to bMSCs may be due to their
origin from a regenerative tissue, in which the telomerase activity
prevents telomere shortening in early cell culture, and thus delaying
the point at which these cells succumb to replicative senescence.
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